Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | TSPO | P30536 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137835 | 0.98 | C5AR1 (0.43) | C5AR1TSPOCRHR1TSHRKDM4E | |
| SCHEMBL5072433 | 0.94 | C5AR1 (0.43) | C5AR1TSPOCRHR1TSHRHSD11B1 | |
| SCHEMBL5074785 | 0.93 | C5AR1 (0.40) | C5AR1TSPOCRHR1TSHRHDAC1 | |
| SCHEMBL5135659 | 0.93 | P2RX7 (0.41) | C5AR1TSPOCRHR1TSHR | |
| SCHEMBL5135308 | 0.93 | C5AR1 (0.41) | C5AR1TSPOCRHR1TSHRKDM4E | |
| SCHEMBL5074813 | 0.90 | TP53 (0.44) | C5AR1TSPOCRHR1TSHRHDAC1 | |
| SCHEMBL5137363 | 0.90 | C5AR1 (0.44) | C5AR1CRHR1TSHRHSD11B1 | |
| SCHEMBL5137492 | 0.89 | C5AR1 (0.42) | C5AR1CRHR1TSHRKDM4EALDH1A1 | |
| SCHEMBL649835 | 0.89 | P2RX7 (0.43) | C5AR1CRHR1TSHRKDM4EALDH1A1 | |
| SCHEMBL5134961 | 0.88 | C5AR1 (0.43) | C5AR1CRHR1TSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |